About US
Contact us
-
CDMO Samsung Biologics bags $1.2B production contract, bringing total 2024 deal value to $3.3B+With multiple high-profile production pacts already in the books for 2024, CDMO Samsung Biologics has hooked another big one. Samsung has locked down a $1.2 billion contract with an unnamed Asia-base2024/10/10
-
DOJ challenges Johnson & Johnson's talc bankruptcy attempt in TexasWith Johnson & Johnson sweetening the pot and mustering up the support of 83% of those who claim that the company’s talc products caused their cancer, it hadappearedthat the sides were speeding t2024/10/15
-
Pfizer lays off 75 more workers in North Carolina in wake of late-stage DMD trial failPfizer has told 75 employees in Sanford, North Carolina, that their positions have been eliminated. The layoffs come three months after the company axed 150 positions in Sanford following a high-prof2024/10/15
-
Amid geopolitical tensions, Legend sheds Genscript as its majority shareholderLegend Biotech has managed to remove Genscript Biotech as its majority shareholder, just as the former parent’s Chinese background falls under a U.S. biosecurity microscope. After a financial maneuve2024/10/17
-
Red light, green light: England's NICE not sold on Lilly's Kisunla despite UK approvalEli Lilly’s Alzheimer’s disease offering Kinsunla is poised to face a tough road ahead in the U.K. While the region’s Medicines and Healthcare products Regulatory Agency (MHRA) signed off on an appro2024/10/17
-
Roche's Vabysmo will rise above Eylea biosim threat, exec says, as DMD gene therapy Elevidys delivers sales surpriseBy squeezing Regeneron’s Eylea, eye disease drug Vabysmo has become one of the biggest growth drivers for Roche. But will the potential imminent launch of a copycat to Eylea stifle Vabysmo’s market e2024/10/22
-
Novo Nordisk asks FDA to prevent compounders from making copycat versions of GLP-1 star semaglutideThe war is on between compounding pharmacies making knockoff versions of popular weight loss drugs and pharma giants Novo Nordisk and Eli Lilly, who want to protect their right to sell their patent2024/10/22
-
In boon for Pfizer and Merck, CDC panel backs expanded use of pneumococcal vaccinesWith an expanded usage recommendation from the CDC's Advisory Committee on Immunization Practices (ACIP), pneumococcal conjugate vaccines from Pfizer and Merck are poised to add millions more eligibl2024/10/25
-
GSK answers Pfizer's RSV approval with data targeting matching nod in younger adultsPreliminary results from two trials showed that GSK’s respiratory syncytial virus (RSV) vaccine Arexvyhas potentialin younger adults with certain risk factors, potentially positioning the shot for a2024/10/25
-
ESMO: Merck unpacks a mixed bag of gynecological cancer results for KeytrudaEven for Merck’s oncology powerhouse Keytruda, the emerging role of immunotherapies in gynecological cancer treatment represents a bit of a mixed bag. While earlier this year Keytruda seemed to shine2024/9/20